{"id":"dexemedetomidine-and-rocuronium","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Muscle weakness or paralysis (expected pharmacologic effect)"},{"rate":null,"effect":"Respiratory depression or apnea"}]},"_chembl":{"chemblId":"CHEMBL1200648","moleculeType":"Small molecule","molecularWeight":"609.69"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Dexemedetomidine binds to alpha-2 adrenergic receptors in the central nervous system to produce dose-dependent sedation, analgesia, and anxiolysis without respiratory depression. Rocuronium competitively blocks acetylcholine at the neuromuscular junction, causing reversible skeletal muscle paralysis. Together, this combination is used for procedural sedation and anesthesia support.","oneSentence":"Dexemedetomidine is a selective alpha-2 adrenergic agonist that provides sedation and analgesia, while rocuronium is a neuromuscular blocking agent that paralyzes skeletal muscles.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:51.574Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Procedural sedation and anesthesia support (phase 3 investigational)"}]},"trialDetails":[{"nctId":"NCT04709315","phase":"PHASE3","title":"Rapid Sequence Induction: Succinyl Choline vs Rocuronium After Pretreatment With Dexmedetomidine","status":"UNKNOWN","sponsor":"South Valley University","startDate":"2020-10-01","conditions":"Rapid Sequence Induction","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"dexemedetomidine and rocuronium","genericName":"dexemedetomidine and rocuronium","companyName":"South Valley University","companyId":"south-valley-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexmedetomidine is a medication used in the context of rapid sequence induction, as seen in clinical trials such as NCT04709315. Rocuronium is a muscle relaxant used in rapid sequence induction, often compared to succinyl choline in clinical trials, including NCT04709315.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}